CY1114051T1 - Φαρμακευτικο στερεο παρασκευασμα τυπου πλεγματος - Google Patents
Φαρμακευτικο στερεο παρασκευασμα τυπου πλεγματοςInfo
- Publication number
- CY1114051T1 CY1114051T1 CY20131100466T CY131100466T CY1114051T1 CY 1114051 T1 CY1114051 T1 CY 1114051T1 CY 20131100466 T CY20131100466 T CY 20131100466T CY 131100466 T CY131100466 T CY 131100466T CY 1114051 T1 CY1114051 T1 CY 1114051T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sugar
- pharmaceutical solid
- solid grade
- gastrointestinal tract
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση σκοπεύει στην παροχή ενός στερεού παρασκευάσματος τύπου πλέγματος που έχει υψηλού επιπέδου ικανότητα ελέγχου της απελευθερώσεως για την καταστολή της απελευθερώσεως του φαρμάκου στην ανώτερη γαστρεντερική οδό και την επιτάχυνση της απελευθερώσεως του φαρμάκου στην κατώτερη γαστρεντερική οδό, και όλα αυτά επιλύουν τα μειονεκτήματα τα προκαλούμενα από το συνδυασμό ενός πλαστικοποιητή. Η παρούσα εφεύρεση παρέχει ένα φαρμακευτικό στερεό παρασκεύασμα τύπου πλέγματος που περιέχει: (a) ένα εντερικό πολυμερές βάσει μεθακρυλικού οξέος• και (b) ένα σάκχαρο και/ή μία σακχαρούχο αλκοόλη, όπου 1 g του σακχάρου ή της σακχαρούχου αλκοόλης μπορεί να διαλυθεί εντός όχι περισσότερο από 4g ύδατος σε θερμοκρασία ύδατος των 20 έως 25°C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007272700 | 2007-10-19 | ||
EP08838805.3A EP2180882B2 (en) | 2007-10-19 | 2008-09-26 | Solid matrix pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114051T1 true CY1114051T1 (el) | 2016-07-27 |
Family
ID=40567911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100466T CY1114051T1 (el) | 2007-10-19 | 2013-06-11 | Φαρμακευτικο στερεο παρασκευασμα τυπου πλεγματος |
Country Status (24)
Country | Link |
---|---|
US (2) | US9072670B2 (el) |
EP (1) | EP2180882B2 (el) |
JP (1) | JP4879351B2 (el) |
KR (2) | KR101600099B1 (el) |
CN (1) | CN101854920B (el) |
AR (1) | AR068910A1 (el) |
AU (1) | AU2008313032B2 (el) |
BR (1) | BRPI0817822A2 (el) |
CA (1) | CA2702904A1 (el) |
CY (1) | CY1114051T1 (el) |
DK (1) | DK2180882T3 (el) |
ES (1) | ES2406939T3 (el) |
HK (1) | HK1144775A1 (el) |
HR (1) | HRP20130498T1 (el) |
IL (1) | IL204706A (el) |
MX (1) | MX2010004178A (el) |
MY (1) | MY147827A (el) |
PL (1) | PL2180882T3 (el) |
PT (1) | PT2180882E (el) |
RU (2) | RU2465916C2 (el) |
SI (1) | SI2180882T1 (el) |
TW (1) | TWI433679B (el) |
WO (1) | WO2009051022A2 (el) |
ZA (1) | ZA201002211B (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2619547C (en) | 2007-02-06 | 2016-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
US7942219B2 (en) | 2007-03-21 | 2011-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
US9297211B2 (en) | 2007-12-17 | 2016-03-29 | Smith International, Inc. | Polycrystalline diamond construction with controlled gradient metal content |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
WO2010009430A2 (en) | 2008-07-17 | 2010-01-21 | Smith International, Inc. | Methods of forming thermally stable polycrystalline diamond cutters |
CN102020609A (zh) * | 2009-09-17 | 2011-04-20 | 北京本草天源药物研究院 | 托伐普坦晶体或无定形物及其制备方法 |
CN102293734A (zh) * | 2010-06-25 | 2011-12-28 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
CN102552278A (zh) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | 一种提高难溶性药物托伐普坦溶出度的药物组合物 |
CN102558051B (zh) * | 2011-07-15 | 2016-08-10 | 天津泰普药品科技发展有限公司 | 一种托伐普坦晶体及其药物组合物 |
CN103007286B (zh) * | 2011-09-28 | 2016-06-15 | 北京本草天源药物研究院 | 一种托伐普坦的固体药物组合物 |
TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
TWI660748B (zh) * | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液 |
CN103880747B (zh) * | 2014-03-20 | 2015-08-26 | 成都百裕科技制药有限公司 | 无定形托伐普坦的制备方法 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN106511351B (zh) * | 2016-12-27 | 2020-04-03 | 吉林省博大伟业制药有限公司 | 聚普瑞锌在制备抗幽门螺旋杆菌药物中的应用 |
CN108478581A (zh) * | 2018-05-09 | 2018-09-04 | 南通大学 | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 |
KR102138253B1 (ko) * | 2018-08-17 | 2020-07-29 | 한국유나이티드제약 주식회사 | 실로스타졸 서방성 제제 |
WO2022150535A1 (en) * | 2021-01-08 | 2022-07-14 | Board Of Trustees Of Michigan State University | Methods for forming cellulosic-based containers, related articles, and related compositions |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US202090A (en) * | 1878-04-09 | Improvement in plows | ||
US3491070A (en) * | 1966-11-25 | 1970-01-20 | Goodrich Co B F | 2 - ethylhexyl acrylate - n - octyl acrylamide - methacrylamide / acrylamide terpolymer |
JPS6051106A (ja) | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US5209933A (en) † | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
JPH0443049A (ja) | 1990-06-08 | 1992-02-13 | Ricoh Co Ltd | サーマルヘッドと厚膜金電極へのメッキ方法 |
SE9100284D0 (sv) † | 1991-01-30 | 1991-01-30 | Astra Ab | Novel peptide |
JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
JPH06199657A (ja) | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
JPH115739A (ja) † | 1997-06-17 | 1999-01-12 | Taisho Yakuhin Kogyo Kk | ベザフィブラート含有持続性製剤およびその製造方法 |
EP1027036A2 (en) | 1997-10-03 | 2000-08-16 | ELAN CORPORATION, Plc | Taste masked formulations |
JP2002510336A (ja) | 1998-04-11 | 2002-04-02 | エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ | 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法 |
CN1272785A (zh) * | 1998-06-11 | 2000-11-08 | Em工业股份有限公司 | 微渗透药物控释系统 |
FR2781152B1 (fr) † | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
GT199900148A (es) * | 1998-09-10 | 2001-02-28 | Desnaturalizantes para las sales aminas simpaticomimeticas. | |
IN191239B (el) * | 1999-06-11 | 2003-10-11 | Ranbaxy Lab Ltd | |
DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
DE10046541A1 (de) * | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
KR100994221B1 (ko) * | 2001-06-14 | 2010-11-12 | 오츠카 세이야쿠 가부시키가이샤 | 의약 조성물 |
WO2003009831A1 (en) | 2001-07-27 | 2003-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same |
MXPA04002980A (es) † | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas. |
NZ533784A (en) | 2002-01-03 | 2006-08-31 | Smithkline Beecham Corp | Novel pharmaceutical dosage forms and method for producing same |
WO2003082204A2 (en) * | 2002-03-26 | 2003-10-09 | Euro-Celtique S.A. | Sustained-release gel coated compositions |
US6946156B2 (en) † | 2002-05-15 | 2005-09-20 | Mcneil-Ppc, Inc. | Process for enrobing a core |
WO2004054568A1 (en) * | 2002-12-17 | 2004-07-01 | Abbott Gmbh & Co. Kg | Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050147663A1 (en) † | 2003-07-17 | 2005-07-07 | Mohan Mailatur S. | Method of treatment for improved bioavailability |
JP2005206490A (ja) † | 2004-01-21 | 2005-08-04 | Pola Chem Ind Inc | 経口投与用の組成物 |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US20050196355A1 (en) † | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
US20050196447A1 (en) † | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
CA2589493A1 (en) † | 2004-12-17 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising telmisartan and hydrochlorothiazide |
US20060159753A1 (en) | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
JP2009500318A (ja) * | 2005-06-29 | 2009-01-08 | パナセア バイオテック リミテッド | 新規な徐放性医薬組成物とその製法 |
CN101384250A (zh) * | 2005-11-09 | 2009-03-11 | 诺瓦提斯公司 | 利用临时增塑剂制备药物组合物的方法 |
SG2014009252A (en) | 2005-12-22 | 2014-05-29 | Otsuka Pharma Co Ltd | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol |
MX2008009267A (es) * | 2006-01-21 | 2008-10-09 | Abbott Gmbh & Co Kg | Forma farmaceutica y metodo para la administracion de farmacos de abuso. |
WO2007086536A2 (en) † | 2006-01-24 | 2007-08-02 | R-Tech Ueno, Ltd. | Soft-gelatin capsule formulation |
-
2008
- 2008-09-26 BR BRPI0817822 patent/BRPI0817822A2/pt not_active IP Right Cessation
- 2008-09-26 KR KR1020107010823A patent/KR101600099B1/ko not_active IP Right Cessation
- 2008-09-26 DK DK08838805.3T patent/DK2180882T3/da active
- 2008-09-26 PT PT88388053T patent/PT2180882E/pt unknown
- 2008-09-26 EP EP08838805.3A patent/EP2180882B2/en not_active Not-in-force
- 2008-09-26 MY MYPI2010001418A patent/MY147827A/en unknown
- 2008-09-26 CN CN2008801122390A patent/CN101854920B/zh not_active Expired - Fee Related
- 2008-09-26 PL PL08838805T patent/PL2180882T3/pl unknown
- 2008-09-26 RU RU2010119926/15A patent/RU2465916C2/ru not_active IP Right Cessation
- 2008-09-26 AU AU2008313032A patent/AU2008313032B2/en not_active Ceased
- 2008-09-26 CA CA2702904A patent/CA2702904A1/en not_active Abandoned
- 2008-09-26 KR KR1020157013358A patent/KR20150064227A/ko not_active Application Discontinuation
- 2008-09-26 WO PCT/JP2008/067996 patent/WO2009051022A2/en active Application Filing
- 2008-09-26 SI SI200631571T patent/SI2180882T1/sl unknown
- 2008-09-26 ES ES08838805T patent/ES2406939T3/es active Active
- 2008-09-26 US US12/738,543 patent/US9072670B2/en not_active Expired - Fee Related
- 2008-09-26 JP JP2010515141A patent/JP4879351B2/ja not_active Expired - Fee Related
- 2008-09-26 MX MX2010004178A patent/MX2010004178A/es active IP Right Grant
- 2008-10-02 TW TW097137892A patent/TWI433679B/zh not_active IP Right Cessation
- 2008-10-17 AR ARP080104534A patent/AR068910A1/es unknown
-
2010
- 2010-03-24 IL IL204706A patent/IL204706A/en not_active IP Right Cessation
- 2010-03-29 ZA ZA2010/02211A patent/ZA201002211B/en unknown
- 2010-12-02 HK HK10111260.8A patent/HK1144775A1/xx not_active IP Right Cessation
-
2012
- 2012-07-30 RU RU2012132627/15A patent/RU2600797C2/ru not_active IP Right Cessation
-
2013
- 2013-06-06 HR HRP20130498AT patent/HRP20130498T1/hr unknown
- 2013-06-11 CY CY20131100466T patent/CY1114051T1/el unknown
-
2015
- 2015-02-06 US US14/615,661 patent/US9289389B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114051T1 (el) | Φαρμακευτικο στερεο παρασκευασμα τυπου πλεγματος | |
CY1121492T1 (el) | Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης και πρεγκαμπαλινης ή γκαμπαπεντινης | |
CY1121801T1 (el) | Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος | |
CY1113882T1 (el) | Φαρμακευτικες συνθεσεις κυκλοσπορινης (cyclosporin) | |
BR112013004440A2 (pt) | método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral | |
ES2523959T3 (es) | Conector de dispositivo medico | |
CY1119746T1 (el) | Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων | |
BR112015014462A2 (pt) | vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos | |
EA200970726A1 (ru) | Твердый препарат, содержащий алоглиптин и пиоглитазон | |
EA200970088A1 (ru) | Модуляторы метаболизма и лечение связанных с ним нарушений | |
EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
CY1122928T1 (el) | Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος | |
CL2009002073A1 (es) | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. | |
AR062583A1 (es) | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan | |
CY1117118T1 (el) | Φαρμακευτικος συνδυασμος για την αγωγη του πονου | |
UY29395A1 (es) | Formulación de medicamentos conteniendo vardenafilo. | |
ES2917982T3 (es) | Método para tratar trastornos hepáticos | |
BR112012009182A2 (pt) | nanopartículas fotointegradas para alvejamento de célula e tecido | |
EA201270581A1 (ru) | Фармацевтические композиции севеламера | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
EA200701228A1 (ru) | Стабильные композиции фенофибрата с эфирами жирных кислот | |
CY1121470T1 (el) | Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης | |
CU23701A1 (es) | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i | |
MA32305B1 (fr) | Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine |